Back to top

Image: Bigstock

Neogen Corporation

Read MoreHide Full Article

Neogen continues to report robust revenue performance on growth across all segments. The company is currently progressing well with the integration process related to several acquisitions within its genomics business, including the recent purchase of laboratories in Brazil and Australia. We are upbeat about the recent buyout of a leading animal genomics laboratory in Canada. Internationally, Neogen is expanding its business rapidly. The company witnessed revenue growth in Europe, Brazil and India along with other geographies in the reported quarter.  However, Neogen has been facing pricing pressure and supply challenges in the animal protein sector. Tough competition also weighs on the stock. Escalating operating expenses add to the woes. Moreover, valuation looks stretched at this moment. Overall, shares of Neogen have underperformed its industry over the past six months.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Neogen Corporation (NEOG) - free report >>

Published in